Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:Q06643 (non-Hodgkin's lymphoma)
 11,307 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Thymidine kinase (TK) is a cellular enzyme which is involved in a "salvage pathway" of DNA synthesis. It is activated in the G1/S phase of the cell cycle, and its activity has been shown to correlate with the proliferative activity of tumor cells. Additionally, certain viruses are able to induce cellular TK production and activity. Clinical studies have reported elevated serum TK levels in a variety of neoplasias. The majority of these studies concerned hematologic malignancies. TK seems to be a useful marker in non-Hodgkin's lymphoma, where it correlates with clinical staging and provides significant prognostic information on (progression-free) survival. Preliminary results in acute myeloid leukemia indicate that pretreatment serum TK values may predict the response to the first induction chemotherapy. Moreover, serum TK appears to have some clinical value in such solid tumors as prostate cancer, breast cancer, and small-cell lung cancer, whereas it is not a reliable marker of non-small-cell lung cancer and brain tumors.
 ...
PMID:Thymidine kinase: a tumor marker with prognostic value for non-Hodgkin's lymphoma and a broad range of potential clinical applications. 164 53

Thymidine kinase (TK) isoenzymes and thymidine phosphorylase (TP) activities have been measured in peripheral mononuclear cells of patients with acute lymphoblastic and monoblastic leukaemia or B-chronic lymphocytic leukaemia, as well as in normal subjects, and also in lymph node cells from patients with non-Hodgkin's lymphoma, with Hodgkin's disease and with benign adenopathies. TK1 isoenzyme activity was highest in acute lymphoblastic leukaemia and in centroblastic lymphoma. Then in progressively decreasing order appeared the Hodgkin's disease values, the centroblastic centrocytic lymphoma values and the benign reactive lymph node cell values. When compared to normal blood mononuclear cells, TP was greatly decreased in acute lymphoblastic leukaemia and slightly but significantly decreased in chronic leukaemia. Monoblastic cells exhibited a unique enzyme pattern; moderately increased TK1 activity and high TP activity. Our results suggest that both enzymes are indicative of the maturation status of leukaemic cells from B lineage. They demonstrate that in lymph node cells, TK1 reflects the proliferative status of both malignant and non-malignant cells and that in monoblastic cells the synthesis of dTMP through de novo synthesis is favoured.
 ...
PMID:Thymidine kinase and thymidine phosphorylase activities in various types of leukaemia and lymphoma. 653

Thymidine kinase (TK) is a cellular enzyme which is involved in a 'salvage pathway' of DNA synthesis. It is activated in the G1/S phase of the cell cycle, and its activity has been shown to correlate with the proliferative activity of tumor cells.... Clinical studies have reported high serum TK concentrations in a variety of neoplasias. The majority of these studies concerned hematological malignancies. TK seems to be a useful marker in non-Hodgkin's lymphoma, where it correlates with clinical staging and provides marked prognostic information on (progression-free) survival.
 ...
PMID:Serum thymidine kinase activity: an alternative to histologic markers of cellular proliferation in canine lymphoma. 1551 87

Thymidine kinase 1 (TK1) is converting thymidine to thymidine monophosphate, and is related to DNA replication and cell proliferation. The use of the TK1 protein levels as a proliferation marker in malignancies is here summarized. TK1 protein in serum (STK1p) and TK1 expression in tissues were determined by a chemoluminescent dot blot assay and by immunohistochemistry staining, respectively. The expression of TK1 in tumor tissues correlated to pathological stages and clinical grades of carcinomas (ca) of esophagus, lung and in premalignancy of breast ductal ca. STK1p could monitor the out-come of tumor therapy by being correlated to remission [breast ca, non-Hodgkin's lymphoma], relapse [breast ca] and to survival [non-Hodgkin's lymphoma] of patients. In a health screening study of 12,641 persons, STK1p seemed to predict the risk of development of neoplasia related diseases at early stage.
 ...
PMID:Thymidine kinase 1 is a potential marker for prognosis and monitoring the response to treatment of patients with breast, lung, and esophageal cancer and non-Hodgkin's lymphoma. 2054 19